# Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)

> **NCT06809764** · — · RECRUITING · sponsor: **Daiichi Sankyo** · enrollment: 150 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **OTHER:** No drug

## Key facts

- **NCT ID:** NCT06809764
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-21
- **Primary completion:** 2027-02-12
- **Final completion:** 2027-02-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06809764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06809764, "Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06809764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*